← Back to Search

Treatment for Juvenile Idiopathic Arthritis

N/A
Recruiting
Led By Adam Huber, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at one year
Awards & highlights

Summary

Juvenile Idiopathic Arthritis (JIA) is a disorder of unknown cause characterized by chronic inflammation of the joints and other organs. It affects about 1 in a 1000 Canadian children and if untreated it can produce lifelong disability. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) includes most pediatric rheumatologists in Canada. They have successfully collaborated for the past 20 years producing groundbreaking research on the modern course and outcomes of JIA. The CAPRI JIA Registry is an ongoing universal registry of Canadian children with JIA that collects longitudinal data on disease course, outcomes and adverse events to inform healthcare decisions and to gain new insights into the disease and its treatment.

Eligible Conditions
  • Juvenile Idiopathic Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of Children with Clinical inactive disease
Secondary study objectives
Childhood Health Assessment Questionnaire Disability Index
Juvenile Arthritis Disease Activity Score
Juvenile Arthritis Quality of Life Questionnaire
+1 more

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,451 Previous Clinical Trials
2,481,952 Total Patients Enrolled
IWK Health CentreOTHER
126 Previous Clinical Trials
101,344 Total Patients Enrolled
Alberta Children's HospitalOTHER
54 Previous Clinical Trials
42,841 Total Patients Enrolled
~183 spots leftby Feb 2026